AbbVie Projects Strong 2026 Growth as Skyrizi and Rinvoq Replace Humira
Feb 13, 2026
AbbVie projects 43-45% earnings growth in 2026 as newer immunology drugs Skyrizi and Rinvoq offset declining Humira sales, while maintaining its 54-year dividend increase streak as a Dividend King.